‘First of its kind’ medication can significantly reduce heart attacks and strokes
A groundbreaking new study suggests that sotagliflozin, a drug recently approved to treat type 2 diabetes and kidney disease ...
TCTMD1mon
Sotagliflozin Reduces Ischemic Risk in SCORED Analysis
Sotagliflozin (Inpefa; Lexicon Pharmaceuticals), a dual sodium-glucose co-transporter 1/2 inhibitor, appears to reduce both MACE and stroke risk among patients with type 2 diabetes, chronic kidney ...
Monthly Prescribing Reference28d
Sotagliflozin Reduces Stroke Risk in Patients With Diabetes, CKD
Sotagliflozin reduces the rate of stroke among patients with diabetes and chronic kidney disease. Sotagliflozin reduces stroke risk among patients with diabetes and chronic kidney disease ...
Medscape28d
Dual SGLT1/2 Inhibitor Protects Against MI and Stroke
The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...